M Machtay

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Oncol 20:3964-71. 2002
  2. ncbi Complex and controversial issues in locally advanced non-small cell lung carcinoma
    Mitchell Machtay
    University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Semin Surg Oncol 21:128-37. 2003
  3. ncbi A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer
    M Machtay
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104, USA
    Int J Radiat Oncol Biol Phys 44:311-5. 1999
  4. ncbi Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    J Thorac Cardiovasc Surg 127:108-13. 2004
  5. ncbi Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma
    M Machtay
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 19:3912-7. 2001
  6. ncbi Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck
    D I Rosenthal
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Oncol 19:1363-73. 2001
  7. ncbi Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment
    A S DeNittis
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Otolaryngol 22:329-35. 2001
  8. ncbi Significance of pretreatment hemoglobin level in patients with T1 glottic cancer
    D J Canaday
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, USA
    Radiat Oncol Investig 7:42-8. 1999
  9. ncbi Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
    M V Pilepich
    Department of Radiation Oncology, Ann Arbor Regional CCOP, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 50:1243-52. 2001
  10. ncbi Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 49:947-56. 2001

Detail Information

Publications50

  1. ncbi Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Oncol 20:3964-71. 2002
    ..To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma...
  2. ncbi Complex and controversial issues in locally advanced non-small cell lung carcinoma
    Mitchell Machtay
    University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Semin Surg Oncol 21:128-37. 2003
    ..This article summarizes the advances in the treatment of locally advanced NSCLC over the past several decades and explores some of the many remaining controversies and areas for future investigation...
  3. ncbi A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer
    M Machtay
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104, USA
    Int J Radiat Oncol Biol Phys 44:311-5. 1999
    ....
  4. ncbi Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    J Thorac Cardiovasc Surg 127:108-13. 2004
    ....
  5. ncbi Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma
    M Machtay
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 19:3912-7. 2001
    ..Some studies report a high risk of death from intercurrent disease (DID) after postoperative radiotherapy (XRT) for non-small-cell lung cancer (NSCLC). This study determines the risk of DID after modern-technique postoperative XRT...
  6. ncbi Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck
    D I Rosenthal
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Oncol 19:1363-73. 2001
    ..This National Cancer Institute-sponsored phase I trial was designed to determine the feasibility of combining continuous-infusion (CI) paclitaxel with concurrent radiation therapy (RT)...
  7. ncbi Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment
    A S DeNittis
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Otolaryngol 22:329-35. 2001
    ..These data provide a baseline for comparison with maturing results from multimodality trials in which radical surgery is not used in all patients with locally advanced oropharyngeal carcinoma...
  8. ncbi Significance of pretreatment hemoglobin level in patients with T1 glottic cancer
    D J Canaday
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, USA
    Radiat Oncol Investig 7:42-8. 1999
    ..This suggests that patients with lower pretreatment Hgb may have confounding medical problems that detract from their overall survival...
  9. ncbi Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
    M V Pilepich
    Department of Radiation Oncology, Ann Arbor Regional CCOP, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 50:1243-52. 2001
    ..To test the hypothesis that androgen ablation before and during radiotherapy for locally advanced carcinoma of the prostate may, by reducing tumor bulk and enhancing tumor cell kill, improve locoregional control and ultimately survival...
  10. ncbi Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 49:947-56. 2001
    ..This analysis excludes those patients with positive lymph nodes or postprostatectomy to determine the benefit of adjuvant hormones in men with locally advanced nonmetastatic prostate cancer receiving definitive RT...
  11. ncbi RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck
    S A Spencer
    Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    Int J Radiat Oncol Biol Phys 51:1299-304. 2001
    ..This study was undertaken to explore the feasibility and toxicity, and estimate the therapeutic impact of, reirradiation (RRT) with concurrent hydroxyurea and 5-fluorouracil...
  12. ncbi Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma
    T J Robnett
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 19:1344-9. 2001
    ..We analyzed our chemoradiation experience for patients at highest risk for the brain as the first failure site...
  13. ncbi Lung and aero-digestive cancers in young marijuana smokers
    M Fung
    Department of Radiation Oncology, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Tumori 85:140-2. 1999
    ..It is hoped that our case presentation can help to stimulate further awareness and research into this issue...
  14. ncbi Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography
    P Li
    Department of Radiology, University of Pennsylvania, Philadelphia, USA
    Clin Nucl Med 26:131-5. 2001
    ..However, single SUV quantification does not significantly enhance efficacy...
  15. ncbi Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Clin Oncol 23:2145-54. 2005
    ..To test the ability of the cytoprotectant, amifostine, to reduce chemoradiotherapy-induced esophagitis and evaluate its influence on quality of life (QOL) and swallowing symptoms...
  16. ncbi Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705
    Jeffrey D Bradley
    Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
    J Clin Oncol 23:3480-7. 2005
    ....
  17. ncbi Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience
    Mitchell Machtay
    Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 63:667-71. 2005
    ..Further study of novel radiation-chemotherapy dose/fractionation regimens is warranted...
  18. ncbi Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
    ....
  19. ncbi Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer
    Mitchell Machtay
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19104, USA
    Semin Oncol 32:S9-12. 2005
    ..Extreme caution must be exercised in designing studies of XRT dose intensification with concurrent chemotherapy...
  20. ncbi Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx
    Sue S Yom
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Clin Oncol 28:385-92. 2005
    ..Future efforts may focus on the improved selection of patients who would be most likely to require early surgical intervention...
  21. ncbi Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
    Mitchell Machtay
    Jefferson Medical College and Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 26:3582-9. 2008
    ..This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT...
  22. ncbi Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrument
    Heather A Jones
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Am J Clin Oncol 29:158-62. 2006
    ..CONCLUSION: The HNDS is a valid measure of acute symptom distress and appears able to discriminate between the chemoradiation and radiation alone patients. There is considerable variation in symptoms that cause these patients distress...
  23. ncbi Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
    Stuart J Wong
    Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    J Clin Oncol 24:2653-8. 2006
    ....
  24. ncbi Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:38-45. 2006
    ....
  25. ncbi Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)
    Mitchell Machtay
    Thomas Jefferson University College of Medicine, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 69:1008-17. 2007
    ..To determine whether the addition of recombinant human erythropoietin (Epo) could improve the outcomes of anemic patients receiving definitive radiotherapy for squamous cell carcinoma of the head and neck (SCCHN)...
  26. ncbi Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck
    Sharon A Spencer
    Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Head Neck 30:281-8. 2008
    ....
  27. ncbi Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer
    Andrew Cupino
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    Otolaryngol Head Neck Surg 137:416-21. 2007
    ..This study evaluated the strategy of performing neck dissection (ND) without primary tumor resection prior to definitive chemoradiotherapy (CRT) for N2+ oropharynx cancer...
  28. ncbi Gustatory impairment in patients undergoing head and neck irradiation
    Natasha Mirza
    Department of Otolaryngology, Head and Neck Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Laryngoscope 118:24-31. 2008
    ..To determine whether radiation alters taste function and structure...
  29. ncbi Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer
    Mary K Bucci
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Am J Clin Oncol 27:595-602. 2004
    ..LRC and survival compare favorably with other aggressive regimens for this poor-prognosis population. Further study of accelerated XRT with concurrent chemotherapy is indicated...
  30. ncbi Signaling pathways in NSCLC as a predictor of outcome and response to therapy
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lung 182:151-62. 2004
    ..This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation...
  31. ncbi Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients
    Theodore J Robnett
    Radiation Oncology Centers, a division of Radiological Associates of Sacramento Medical Group, California, USA
    Cancer J 8:263-7. 2002
    ..DISCUSSION: Our analysis supports the hypothesis that response to chemoradiation of non-small cell lung carcinoma improves with increasing hemoglobin levels...
  32. ncbi A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)
    Jeffrey D Bradley
    Radiation Oncology Center, Washington University Medical Center, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 52:1173-9. 2002
    ..Based on these data, the Radiation Therapy Oncology Group (RTOG) initiated a Phase III trial to test the efficacy of beta-interferon in poor-risk patients with Stages IIIA and IIIB non-small-cell lung carcinoma...
  33. ncbi Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Clin Cancer Res 8:885-92. 2002
    ..We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome...
  34. ncbi Combined modality therapy for non-small cell lung carcinoma
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104-4283, USA
    Cancer J 8:S55-67. 2002
    ..Targeted therapies appear promising, and expedited evaluation in Stage III NSCLC is warranted...
  35. ncbi The early rad catches the tumor?
    Mitchell Machtay
    J Clin Oncol 20:3045-7. 2002
  36. ncbi A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer
    David I Rosenthal
    Department of Radiation Oncology, Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
    Invest New Drugs 20:343-9. 2002
    ..We performed a Phase I study of Stealth liposomal cisplatin (SPI-077) concurrent with RT for head and neck squamous cell carcinoma (HNSCC)...
  37. ncbi Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation
    Jeffrey C Haynes
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Laryngoscope 112:1883-7. 2002
    ..Although the relative risk is approximately doubled, the absolute risk is modest in comparison to the risk of cancer recurrence. Further study of this association and possible interventions is warranted...
  38. ncbi Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck
    David I Rosenthal
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Donner, Philadelphia, PA 19104, USA
    Head Neck 24:115-26. 2002
    ..CONCLUSIONS: A total treatment package time of <100 days is associated with improved tumor control and survival. Every effort should be made to keep the time from surgery to the completion of postoperative RT to <100 days...
  39. ncbi Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer
    Branislav Jeremic
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, D 81675 Munich, Germany
    Hematol Oncol Clin North Am 18:91-100. 2004
    ..Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease...
  40. ncbi Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 59:72-7. 2004
    ..We designed a prospective protocol to determine the feasibility, toxicity, and preliminary efficacy of a regimen of postoperative reirradiation, chemotherapy and the radioprotector amifostine after salvage head-and-neck surgery...
  41. ncbi Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
    Jay S Cooper
    New York University Medical Center, New York, USA
    N Engl J Med 350:1937-44. 2004
    ..However, the combined treatment is associated with a substantial increase in adverse effects...
  42. ncbi Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapy
    Albert S DeNittis
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, U.S.A
    Am J Clin Oncol 25:93-5. 2002
    ..No patient has had a local or neck failure. Chemoradiation plus brachytherapy offers encouraging survival and local-regional control. Further study of this regimen as an alternative or adjunct to intensity-modulated EBXRT is warranted...
  43. ncbi The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
    Cancer 110:911-7. 2007
    ..This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC)...
  44. ncbi Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx
    Andrew R Gordon
    Department of Radiology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    AJNR Am J Neuroradiol 25:1092-8. 2004
    ..01). CONCLUSION: Our results suggest that MR imaging-based tumor volumes are reliably reproducible. Such measurements may be important in predicting patient outcome, determining appropriate therapy, and conducting patient follow-up...
  45. ncbi A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer
    Pramila Rani Anne
    Thomas Jefferson University Hospital, Bodine Center for Cancer Research, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 67:445-52. 2007
    ..Intravenous amifostine 200 mg/m2 reduces xerostomia in head-and-neck cancer patients. This Phase II study evaluated subcutaneous (s.c.) amifostine in a similar patient population...
  46. ncbi Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse
    Mitchell Machtay
    Department of Medicine, Pulmonary, Allergy, and Critical Care Division, Thomas Jefferson University Medical Center, Philadelphia, PA 19104, USA
    Radiother Oncol 81:196-205. 2006
    ..There was also a corresponding effect on several early biomarkers of lung injury and decreased apoptosis. There were no significant effects on acute pneumonitis or tumor protection...
  47. ncbi Altered fractionation: a fractional benefit?
    Lori Wirth
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet 368:819-21. 2006
  48. ncbi Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10
    William U Shipley
    Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 54:1302-10. 2002
    ....
  49. ncbi Phase I's, photons, and philosophies: new tactics for exploratory clinical trials of concurrent chemoradiation
    Mitchell Machtay
    J Clin Oncol 22:214-6. 2004
  50. ncbi Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation
    Yuhchyau Chen
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 8647, USA
    Int J Radiat Oncol Biol Phys 64:1442-51. 2006
    ....